𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A Double-Blind, Randomized, Placebo and Active-Controlled Study of Nebicapone for the Treatment of Motor Fluctuations in Parkinson's Disease

✍ Scribed by Joaquim J. Ferreira; Olivier Rascol; Werner Poewe; Cristina Sampaio; José-Francisco Rocha; Teresa Nunes; Luis Almeida; Patrício Soares-da-Silva; on behalf of the BIA-3202-202 Study Investigators

Book ID
118076694
Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
347 KB
Volume
16
Category
Article
ISSN
1755-5930

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A randomized, double-blind, placebo-cont
A randomized, double-blind, placebo-controlled trial of levetiracetam for dyskinesia in Parkinson's disease
✍ Kitty K. Wong; Jane E. Alty; Amanda G. Goy; Sanjay Raghav; David C. Reutens; Pet 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 565 KB

## Abstract ## Background: This randomized double blind, placebo‐controlled crossover study investigated the antidyskinetic effects of levetiracetam in Parkinson's disease. ## Methods: Sixteen participants with levodopa‐induced dyskinesia were enrolled. Hourly videotaped dyskinesia assessments s

Comparison of desipramine and citalopram
Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: A double-blind, randomized, placebo-controlled study
✍ David Devos; Kathy Dujardin; Isabelle Poirot; Caroline Moreau; Olivier Cottencin 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 118 KB 👁 2 views

## Abstract Depression is one of the most common psychiatric disturbances in Parkinson's disease (PD). Recent reviews have highlighted the lack of controlled trials and the ensuing difficulty in formulating recommendations for antidepressant use in PD. We sought to establish whether antidepressants

Botulinum toxin type A for drooling in P
Botulinum toxin type A for drooling in Parkinson's disease: A double-blind, randomized, placebo-controlled study
✍ Giovanni Lagalla; Marzia Millevolte; Marianna Capecci; Leandro Provinciali; Mari 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 65 KB

To investigate the safety and efficacy of botulinum toxin type A (BoNTX) treatment to reduce sialorrhea in Parkinson's disease (PD), a double-blind, randomized, placebo-controlled study enrolled 32 PD patients complaining of excessive drooling. Patients received either 50 U Botox in each parotid gla

A randomized, double-blind, placebo-cont
A randomized, double-blind, placebo-controlled trial of olsalazine for active Crohn's disease
✍ J. P. Wright; Dr. D. P. Jewell; R. Modigliani; H. Malchow 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 486 KB 👁 2 views

Olsalazine, consisting of two salicylate radicals linked by an azo-bond, is effective in the treatment of active ulcerative colitis. To test its effect in patients with mild to moderate attacks of Crohn's disease, the International Organization for the Study of Inflammatory Bowel Disease (IOIBD) des

Rifaximin for the treatment of active po
Rifaximin for the treatment of active pouchitis: A randomized, double-blind, placebo-controlled pilot study
✍ Kim L. Isaacs; Robert S. Sandler; Maria Abreu; Michael F. Picco; Stephen B. Hana 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 132 KB 👁 2 views

## Background: The efficacy of the nonabsorbable antibiotic rifaximin in patients with active acute or chronic pouchitis is unknown. ## Methods: We performed a placebo-controlled pilot trial to evaluate the efficacy and safety of rifaximin in patients with active pouchitis. eighteen patients with

Rotigotine effects on early morning moto
Rotigotine effects on early morning motor function and sleep in Parkinson's disease: A double-blind, randomized, placebo-controlled study (RECOVER)
✍ Claudia Trenkwalder; Bryan Kies; Monika Rudzinska; Jennifer Fine; Janos Nikl; Kr 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 752 KB

In a multinational, double-blind, placebo-controlled trial (NCT00474058), 287 subjects with Parkinson's disease (PD) and unsatisfactory early-morning motor symptom control were randomized 2:1 to receive rotigotine (2–16 mg/24 hr [n = 190]) or placebo (n = 97). Treatment was titrated to optimal dose